(Press-News.org) Article Summary:
Researchers found that DNA’s shape matters. When its loops break, cancer can start.
Based on a new concept of architectural tumor suppression, researchers used proteins that organize DNA to also help prevent lymphoma.
Artificial intelligence helped reveal the changes that could guide future treatments.
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 9:50 A.M. EST) – Cancer isn’t just about broken genes—it’s about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services. That’s what happens inside cells when the 3D structure of DNA collapses.
A new study presented Dec. 6 at the 2025 American Society of Hematology (ASH) meeting, by Martin Rivas, Ph.D., a cancer researcher at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, revealed that even subtle disruptions in genome architecture can predispose individuals to lymphoma. This finding offers a new perspective on understanding and eventually treating blood cancers.
The study, entitled “SMC3 and CTCF Haploinsufficiency Drive Lymphoid Malignancy via 3D Genome Dysregulation and Disruption of Tumor Suppressor Enhancer-Promoter Loops,” introduced a new idea: architectural tumor suppression.
Proteins like SMC3 and CTCF don’t just organize DNA—they actively prevent cancer by maintaining loops that connect gene “switches” (enhancers) to the genes they control (promoters). Lose even half of these proteins, and the loops start disappearing, silencing critical tumor suppressor genes.
“We’ve long known that mutations drive cancer,” said Rivas. “But this work shows that architecture—the way DNA folds—can be just as important. It’s like losing the blueprint for a building while construction is under way.”
Using AI-driven analytics to interpret massive datasets from Hi-C maps, single-cell RNA sequencing and epigenetic profiles, the team uncovered a striking pattern:
SMC3 or CTCF haploinsufficiency (partial loss) doesn’t wreck the entire genome structure. Instead, it erodes short-range enhancer-promoter loops—the wiring that keeps tumor suppressor genes like Tet2, Kmt2d, and Dusp4 active.
Without these loops, B-cells hit a “decision bottleneck” and fail to mature into plasma cells, creating fertile ground for malignancy.
AI tools helped integrate these complex layers of data, revealing how architectural changes ripple through gene expression and cell fate.
“This is where computational biology shines,” Rivas added. “AI allowed us to see patterns invisible to the human eye—how losing just one copy of a gene reshapes the entire 3D landscape.”
The findings aren’t just theoretical. Patients with diffuse large B-cell lymphoma (DLBCL) who have lower SMC3 expression fare worse. This suggests that genome architecture could become a biomarker for prognosis—and maybe a target for therapy. Instead of fixing mutations, future treatments might aim to restore proper looping or mimic its effects.
This research reframes cancer biology: it’s not only about the genetic code but also about the scaffolding that holds it together. By understanding architectural tumor suppression, scientists can explore therapies that stabilize genome structure—an entirely new frontier in oncology.
“We’re entering an era where cancer treatment could mean repairing architecture, not just fixing broken genes,” said Rivas. “That’s a paradigm shift.”
In the end, think back to that city analogy: when the streets disappear, neighborhoods become isolated and life grinds to a halt. Inside cells, when DNA loops vanish, tumor suppressor genes lose their lifelines—and cancer finds a way in. Restoring those connections could be the key to keeping the city—and the cell—alive and thriving.
about Sylvester research on the InventUM blog and follow @SylvesterCancer on X for the latest news on its research and care.
# # #
Scientific Program Title: Enhancer Function in Lymphoid Development and Lymphoma
Presentation Date/Time/Location: Dec. 6, 2025, 9:50-10:10AM EST, OCCC – W312
# # #
END
Article Summary
ACCESS study reveals patients can safely receive stem cell transplants from unrelated donors with multiple genetic mismatches.
A protective regimen acts as a “bridge,” preventing complications and boosting survival rates.
Findings could make transplants accessible to nearly all patients with blood cancers, regardless of ancestry.
Study will be presented at ASH Dec. 8 and will also be highlighted in a special ASH press briefing Dec. 6 at 8:30AM EST.
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 8:30AM) – For years, the ...
(ORLANDO, Dec. 6, 2025) A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, can make the procedure safe and effective even when donors and recipients are unrelated and have extensive genetic mismatches. Historically, genetic compatibility has played a primary role in identifying matched donors; these results suggest that many patients who need a transplant could now have access to a much broader pool of potential donors and expect outcomes comparable to those from fully matched donors.
The study found that one-year survival was similar whether patients received ...
(ORLANDO, Dec. 6, 2025) According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
The study is the first prospective trial to directly compare these two approaches. With a median follow-up of nearly three years, the results show these approaches are essentially equivalent in terms of risk of death or disease progression.
“As clinicians, we often assume ...
(ORLANDO, Dec. 6, 2025) Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term outcomes for patients with acute myeloid leukemia (AML), according to a new study from the HARMONY Alliance.
The study is the first to evaluate MRD as a potential measure of treatment efficacy and outcome prediction in the context of AML. The results suggest that MRD could help refine how physicians assess treatment response and personalize post-remission care. The findings may also help regulators determine whether MRD can serve as an intermediate ...
(ORLANDO, Dec. 6, 2025) In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation. The findings could allow more patients to avoid TBI and its associated long-term side effects.
The study is the first to test the use of chemotherapy-based conditioning in patients with no evidence of measurable residual disease (MRD) through next-generation-sequencing ...
(ORLANDO, Dec. 6, 2025) Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child’s treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities.
“To our knowledge, this is the first study in pediatric oncology to examine the financial impact associated with cancer treatment by measuring household material hardship and income loss over ...
(ORLANDO, Dec. 6, 2025) Within a year of initiation, a multidisciplinary project to improve screening and treatment for iron deficiency in pregnancy resulted in a sixfold rise in screening rates for iron deficiency in pregnant patients, a 20-fold rise in the number of intravenous (IV) iron infusions, and a significant improvement in median hemoglobin levels.
“Screening rates went from 10% to over 60% within a year,” said lead author Richard Godby, MD, a hematologist at the Mayo Clinic in Rochester, Minnesota. “Two-thirds of pregnant patients screened were found to be iron deficient, indicating that this is a very common, but readily fixable problem.”
Women ...
(ORLANDO, Dec. 6, 2025) Treatment with intravenous (IV) iron significantly improved survival and increased hemoglobin levels in patients with iron-deficiency anemia who were hospitalized for an acute bacterial infection, according to an analysis of data from more than 85,000 patients.
“Our data show that it is safe to give IV iron to patients who have both iron-deficiency anemia and an acute bacterial infection, and that, compared with untreated patients, those treated with IV iron have better overall survival and higher hemoglobin levels,” said lead author Haris Sohail, MD, a fellow in hematology-oncology at Charleston Area Medical ...
(ORLANDO, Dec. 6, 2025) Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period and supported by the National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health. Among patients with a mutation in their cancer cells that is generally associated with more favorable outcomes from AML treatment, survival for Black patients was ...
(ORLANDO, Dec. 6, 2025) A new study finds that only one in three patients visiting emergency departments (EDs) for severe pain associated with sickle cell disease received appropriate opioid-based pain-relieving medications within the first hour as recommended by the American Society of Hematology (ASH) and National Heart, Lung, and Blood Institute (NHLBI).
Based on data from several hundred medical centers across the United States, the research represents the first large, national study to assess guideline adherence across diverse EDs. It shows substantially ...
